Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.

Pharmacogenetics and genomics - 1 Jun 2015

Fanciullino Raphaelle, Mercier Cedric, Serdjebi Cindy, Berda Yaël, Fina Frederic, Ouafik L'Houcine, Lacarelle Bruno, Ciccolini Joseph, Costello Regis

Abstract excerpt

Azacytidine, an antimetabolite with an original epigenetic mechanism of action, increases survival in patients diagnosed with high-risk myelodysplasic syndromes or acute myeloid leukemia with less than 30% medullar blasts. Azacytidine is a pyrimidine derivative that undergoes metabolic detoxification driven by cytidine deaminase (CDA), a liver enzyme whose gene is prone to genetic polymorphism, leading to erratic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytarabine

Share to Cytidine Deaminase

Share to Deoxycytidine

Share to Gemcitabine

Share to Inactivation, Metabolic

Share to Myelodysplastic Syndromes

Source

Identifiers

PMID: 25850965
DOI: 10.1097/FPC.0000000000000139

Genes

CDA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.PMID 25850965Read ↗

Cytidine deaminase activity predicts clinical outcome of azacitidine in real-world MDS patientsSemantic proximity Read ↗

Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.Semantic proximity Read ↗

The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?Semantic proximity Read ↗

Why methylation is not a marker predictive of response to hypomethylating agents.Semantic proximity Read ↗

Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.Semantic proximity Read ↗

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabineSemantic proximity Read ↗

Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation.Semantic proximity Read ↗

Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluationSemantic proximity Read ↗

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapySemantic proximity Read ↗

Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.